Nexalin Technology, Inc.

Nexalin Technology manufactures a non-invasive, drug-free medical device for transcranial electrical stimulation (TES) targeting anxiety, depression, and insomnia. The device delivers a patented waveform that stimulates deep midbrain structures to normalize neurochemical imbalances, particularly increasing beta-endorphins and modulating serotonin and dopamine levels. FDA-classified as a non-significant risk device, it delivers 40-minute home-based treatments with no reported side effects. Clinical data indicates 60–80% symptom reduction rates. The company markets to both healthcare providers seeking to establish virtual treatment clinics and direct-to-consumer patients. The technology addresses the growing mental health epidemic in the United States through an evidence-based, medication-free alternative.